Oldroyd AGS, et al. - The experts herein aimed to investigate the long-term persistence of rituximab (RTX) in a large observational RA cohort, as well as the persistence of RTX when used as a first or second line biologic DMARD (bDMARD), to characterize subsequent bDMARD treatment after RTX. Findings suggested that 60% of the patients persisted with treatment after 4 years. When used as a first or second line bDMARD, RTX was seen to be tolerated well. Out of the patients that discontinued RTX, 46% began a treatment with another bDMARD, with tocilizumab being the most common.